Drug intelligence / Profile preview

oxaliplatin + gemcitabine + cisplatin + lipiodol

Development stage: Preclinical
Lead developer: Sanofi
Modality: Small Molecules
Administration: Intra-arterial

Overview

A combination chemotherapy regimen consisting of oxaliplatin, gemcitabine, and cisplatin emulsified with lipiodol (ethiodized oil) for transcatheter arterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC). This combination leverages the cytotoxic effects of the chemotherapy agents while using lipiodol as a carrier to enhance tumor targeting and retention. Lipiodol selectively accumulates in tumor tissue and remains there for extended periods (4+ weeks), allowing for sustained drug delivery and follow-up imaging without re-administration.

Targets

DNA polymerase familyDNA

Beyond the preview

Go deeper on oxaliplatin + gemcitabine + cisplatin + lipiodol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxaliplatin + gemcitabine + cisplatin + lipiodol.

Explore the full profile